Technical Data

366874
CAS Number
556813-39-9
Grade
Highly Purified
MDL Number
MFCD24369684
Molecular Formula
C20H17Cl2N9O2
Molecular Weight
486.3
EU Commodity Code
38220090
Shipping Temp
Blue Ice
Storage Temp
-20°C
CHIR 98014
6-N-[2-[[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine, CHIR98014, CHIR-98014
Synonyms
CHIR98014, CHIR-98014
Chemical Name
6-N-[2-[[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethyl]-3-nitrop yridine-2,6-diamine
Molecular Formula
C20 H17 Cl
Molecular Weight
486.3
CAS Number
556813-39-9
Purity
≥98%
Applications
FA
Appearance
Crystalline solid
Description
CHIR 98014 is a potent and reversible inhibitor of Glycogen Synthase Kinase 3 (GSK3), inhibiting both the alpha (IC50: 0.65 nM) and beta (IC50: 0.58 nM) isoforms. GSK3 functions by phosphorylating a serine or threonine residue on its target substrate and is part of the Wnt pathway that signals the cell to divide and proliferate. CHIR 98014 activates glycogen synthase in cells to improve glucose disposal and to reduce tau phosphorylation in neurons. It is reported to stimulate vascular cell differentiation of hPSC and enhances the transformation of vascular smooth muscle cells into osteogenic-like cells under high phosphate conditions.
Storage
Soluble in organic solvents such as DMSO. DMSO up to 2mM. Product should be kept at -20°C.
Source
Synthetic
Purity
Highly Purified (~98%)
Concentration
Not determined
Form
Supplied as a crystalline solid.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
1. Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Wagman, A. S. (2003). Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes, 52(3), 588-595. 2. Naujok, O., Lentes, J., Diekmann, U., Davenport, C., Lenzen, S. (2014). Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC research notes, 7(1), 1. 3. Lian, X., Bao, X., Al-Ahmad, A., Liu, J., Wu, Y., Dong, W., Palecek, S. P. (2014). Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling.Stem cell reports, 3(5), 804-816. 4. Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Palecek, S. P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings of the National Academy of Sciences, 109(27), E1848-E1857.
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net